Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells

Ichiro Kawashima, Van Tsai, Scott Southwood, Kazutoh Takesako, Alessandro Sette, Esteban Celis

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

The human carcinoembryonic antigen (CEA) and HER-2/neu are potential target antigens for CTL specific immunotherapy for common malignancies such as breast, lung, colon, and gastric carcinomas. Several CTL epitopes restricted by HLA-A2, the most common human histocompatibility molecule, have been previously reported. However, to develop CTL-based immunotherapies for the general population, it is necessary to identify epitopes restricted by other common histocompatibility alleles. Here, we describe two HLA-A3- restricted CTL epitopes from the CEA and HER-2/neu antigens. HLA-A3 binding synthetic peptides from CEA and HER-2/neu were tested for immunogenicity by in vitro primary CTL induction protocol using peripheral blood mononuclear cells from normal healthy volunteers. One peptide from CEA (CEA[961]: HLFGYSWYK) and one peptide from HER-2/neu (HER2[9754]: VLRENTSPK) were shown to induce CTL that was capable of killing a tumor cell line expressing HLA-A3 and the corresponding tumor-associated antigen. Additional MHC binding studies with the most common HLA molecules belonging to the HLA-A3 superfamily (HLA-A*1101, -A*3101, -A*3301, and -A*6801), demonstrated that CEA[961] binds five of five A3 supertype molecules with high affinity, and the HER2[9754] epitope was able to bind to four of the same five alleles. These results indicate that these two new CTL epitopes should be immunogenic in individuals expressing either HLA-A3, or other members of the HLA-A3 superfamily.

Original languageEnglish (US)
Pages (from-to)431-435
Number of pages5
JournalCancer Research
Volume59
Issue number2
StatePublished - Jan 16 1999
Externally publishedYes

Fingerprint

HLA-A3 Antigen
T-Lymphocyte Epitopes
Carcinoembryonic Antigen
Cytotoxic T-Lymphocytes
Dendritic Cells
Immunization
Epitopes
Peptides
Histocompatibility
Immunotherapy
Healthy Volunteers
Alleles
HLA-A2 Antigen
Antigens
HLA-A Antigens
Neoplasm Antigens
Tumor Cell Line
In Vitro Techniques
Blood Cells
Stomach

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. / Kawashima, Ichiro; Tsai, Van; Southwood, Scott; Takesako, Kazutoh; Sette, Alessandro; Celis, Esteban.

In: Cancer Research, Vol. 59, No. 2, 16.01.1999, p. 431-435.

Research output: Contribution to journalArticle

@article{0222da857ea4494e96a711a134a4ebe5,
title = "Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells",
abstract = "The human carcinoembryonic antigen (CEA) and HER-2/neu are potential target antigens for CTL specific immunotherapy for common malignancies such as breast, lung, colon, and gastric carcinomas. Several CTL epitopes restricted by HLA-A2, the most common human histocompatibility molecule, have been previously reported. However, to develop CTL-based immunotherapies for the general population, it is necessary to identify epitopes restricted by other common histocompatibility alleles. Here, we describe two HLA-A3- restricted CTL epitopes from the CEA and HER-2/neu antigens. HLA-A3 binding synthetic peptides from CEA and HER-2/neu were tested for immunogenicity by in vitro primary CTL induction protocol using peripheral blood mononuclear cells from normal healthy volunteers. One peptide from CEA (CEA[961]: HLFGYSWYK) and one peptide from HER-2/neu (HER2[9754]: VLRENTSPK) were shown to induce CTL that was capable of killing a tumor cell line expressing HLA-A3 and the corresponding tumor-associated antigen. Additional MHC binding studies with the most common HLA molecules belonging to the HLA-A3 superfamily (HLA-A*1101, -A*3101, -A*3301, and -A*6801), demonstrated that CEA[961] binds five of five A3 supertype molecules with high affinity, and the HER2[9754] epitope was able to bind to four of the same five alleles. These results indicate that these two new CTL epitopes should be immunogenic in individuals expressing either HLA-A3, or other members of the HLA-A3 superfamily.",
author = "Ichiro Kawashima and Van Tsai and Scott Southwood and Kazutoh Takesako and Alessandro Sette and Esteban Celis",
year = "1999",
month = "1",
day = "16",
language = "English (US)",
volume = "59",
pages = "431--435",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells

AU - Kawashima, Ichiro

AU - Tsai, Van

AU - Southwood, Scott

AU - Takesako, Kazutoh

AU - Sette, Alessandro

AU - Celis, Esteban

PY - 1999/1/16

Y1 - 1999/1/16

N2 - The human carcinoembryonic antigen (CEA) and HER-2/neu are potential target antigens for CTL specific immunotherapy for common malignancies such as breast, lung, colon, and gastric carcinomas. Several CTL epitopes restricted by HLA-A2, the most common human histocompatibility molecule, have been previously reported. However, to develop CTL-based immunotherapies for the general population, it is necessary to identify epitopes restricted by other common histocompatibility alleles. Here, we describe two HLA-A3- restricted CTL epitopes from the CEA and HER-2/neu antigens. HLA-A3 binding synthetic peptides from CEA and HER-2/neu were tested for immunogenicity by in vitro primary CTL induction protocol using peripheral blood mononuclear cells from normal healthy volunteers. One peptide from CEA (CEA[961]: HLFGYSWYK) and one peptide from HER-2/neu (HER2[9754]: VLRENTSPK) were shown to induce CTL that was capable of killing a tumor cell line expressing HLA-A3 and the corresponding tumor-associated antigen. Additional MHC binding studies with the most common HLA molecules belonging to the HLA-A3 superfamily (HLA-A*1101, -A*3101, -A*3301, and -A*6801), demonstrated that CEA[961] binds five of five A3 supertype molecules with high affinity, and the HER2[9754] epitope was able to bind to four of the same five alleles. These results indicate that these two new CTL epitopes should be immunogenic in individuals expressing either HLA-A3, or other members of the HLA-A3 superfamily.

AB - The human carcinoembryonic antigen (CEA) and HER-2/neu are potential target antigens for CTL specific immunotherapy for common malignancies such as breast, lung, colon, and gastric carcinomas. Several CTL epitopes restricted by HLA-A2, the most common human histocompatibility molecule, have been previously reported. However, to develop CTL-based immunotherapies for the general population, it is necessary to identify epitopes restricted by other common histocompatibility alleles. Here, we describe two HLA-A3- restricted CTL epitopes from the CEA and HER-2/neu antigens. HLA-A3 binding synthetic peptides from CEA and HER-2/neu were tested for immunogenicity by in vitro primary CTL induction protocol using peripheral blood mononuclear cells from normal healthy volunteers. One peptide from CEA (CEA[961]: HLFGYSWYK) and one peptide from HER-2/neu (HER2[9754]: VLRENTSPK) were shown to induce CTL that was capable of killing a tumor cell line expressing HLA-A3 and the corresponding tumor-associated antigen. Additional MHC binding studies with the most common HLA molecules belonging to the HLA-A3 superfamily (HLA-A*1101, -A*3101, -A*3301, and -A*6801), demonstrated that CEA[961] binds five of five A3 supertype molecules with high affinity, and the HER2[9754] epitope was able to bind to four of the same five alleles. These results indicate that these two new CTL epitopes should be immunogenic in individuals expressing either HLA-A3, or other members of the HLA-A3 superfamily.

UR - http://www.scopus.com/inward/record.url?scp=0033556012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033556012&partnerID=8YFLogxK

M3 - Article

C2 - 9927058

AN - SCOPUS:0033556012

VL - 59

SP - 431

EP - 435

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 2

ER -